This trial is evaluating whether Treatment will improve 2 primary outcomes and 3 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of 6 years.
This trial requires 315 total participants across 6 different treatment groups
This trial involves 6 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
In the United States, the vast majority of men diagnosed with prostate cancer are treated with androgen blockers or surgery. Additionally, a wide variety of other treatments for prostate cancer are used.
About 0.6 million men experience [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) a year in the United States. This puts them right at the top of the list of cancer diagnoses in the United States.
The most sensitive and specific initial sign of prostate cancer is elevated blood PSA level. Although most of the men with clinically insignificant prostate cancer will not have any prostate cancer-related symptoms or complaints, a small percentage will develop symptoms that are suggestive of prostate cancer. The most important symptom is difficulty in urinating with a concurrent low urinary flow rate and pain in the lower back.
Prostatic carcinoma in young men is treated mainly via radical surgical therapy. Most patients succumb to localised disease which remains asymptomatic. The authors advocate radical surgical intervention with pelvic lymphadenectomy and/or salvage radiation therapy following a positive pelvic examination when radical surgery fails to cure the illness.
Prostate cancer is a cancer that arises in the prostate gland in males. While prostate cancer is uncommon in younger men, it becomes more common as men get older. In men who are diagnosed with prostate cancer, the cancer can be removed surgically with positive margins. However, in most cases, prostate cancer will not be cured after surgery. This is due to the number of risk factors associated with this condition. Most men with prostate cancer can expect to live for at least 10 years (75% of the time) after they receive the first treatment because they may develop an aggressive form of the condition. Although survival rates vary widely between individuals, it is important to understand the risks and benefits of different treatment options before making the best choice.
Active treatment for prostate cancer can provide significant improvements in the quality of life of treated patients. Moreover, the psychological and physical aspects of the prostate cancer treatment are important to consider when designing and evaluating treatment plans and programs.
The study of alternative treatments of this disease is needed; moreover, the development of new treatment algorithms is necessary to optimize the use of available drugs.
Although most side effects occurring with current treatments for prostate cancer have a low frequency it is important to consider that some side effects may be irreversible, as a result of the androgen deprivation therapy.
PSA levels are better than Gleason scores at predicting survival outcomes in [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). They are independent indicators of how far and in what direction the disease has spread. The prognosis of prostate cancer is far worse if the cancer appears to be only locally advanced and limited to the prostate with no evidence of the presence of systemic metastasis. In this group, survival following initial treatment is better. Overall survival averages 10 to 15 years following diagnosis in patients who have had radical prostatectomy even with the most aggressive disease. The disease can persist without treatment but it's still curable.
Inappropriate overuse or underuse of radiotherapy may have an impact on the patients health status. We emphasize the importance that the patients should not suffer from the side effects of external beam radiation therapy or the increased costs of radiotherapy. As a guideline, physicians should consider an individual patient's preferences and expectations. We advise our patients to have a discussion about the benefits and risks of radiotherapy with their doctors.